Trial pairs two dopamine-making genes in one brain infusion for Parkinson's

A phase 1 study delivered a single viral vector carrying both tyrosine hydroxylase and AADC genes into the striatum, aiming for cells that manufacture dopamine on their own rather than depending on oral levodopa. Twelve-month safety data are now published; the trial was not designed to prove the therapy works.

A multicenter, open-label phase 1 trial has reported 12-month safety and tolerability results for a gene therapy that places two genes, tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC), into a single adeno-associated virus (AAV) vector and infuses it directly into the striatum of people with Parkinson's disease. The two enzymes are both required, in sequence, to convert a dietary amino acid precursor into dopamine; earlier gene therapy trials for Parkinson's disease delivered AADC alone, which still leaves patients dependent on external levodopa as the enzyme's raw material. The researchers describe this dual-gene design as aiming for what they call autonomous dopamine synthesis inside striatal cells, meaning the brain tissue would in principle make its own dopamine without an external levodopa supply, published in Nature Medicine.

The report covers safety and tolerability, the standard first question in any phase 1 human gene therapy trial, not whether the treatment relieves Parkinson's symptoms or slows the disease. Phase 1 trials are typically small, run in a handful of participants, and are designed to look for surgical and infusion risks, immune reactions to the viral vector, and any signs the transferred genes behave unexpectedly in brain tissue, not to establish a clinical benefit. Any hints of symptom change reported alongside the safety data in an open-label, uncontrolled trial of this size cannot be separated from the effects of surgery itself, patient and rater expectation, or the natural variability of Parkinson's disease from one visit to the next.

The approach builds on more than a decade of single-gene AAV work in Parkinson's disease, including earlier AADC-only programs whose 36-month safety data have already been reported in the literature, and on decades-old tricistronic vector designs that combined TH, AADC and a third enzyme, GTP cyclohydrolase 1, in preclinical and early clinical work. Whether adding a second gene to the vector meaningfully changes symptoms, reduces medication dependence or carries additional risk compared with those single-gene approaches has not been tested in this trial and will require larger, controlled, longer follow-up studies before any conclusion can be drawn.

The trial's authors and outside reviewers of prior AAV-Parkinson's programs have consistently noted that phase 1 safety trials in a small number of participants cannot show whether a therapy works; that question is reserved for larger, randomized, sham-controlled phase 2 and phase 3 trials, none of which have yet been reported for this dual-gene vector.